ASCO 2015 Highlights

High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
By Wayne Kuznar
Lynch Syndrome
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Based on results of a study presented at ASCO 2018, the presence of an MSI-H or dMMR tumor signature, regardless of cancer type or family history, should prompt genetic testing to evaluate for Lynch syndrome.
Read Article
Cost of Treating Colorectal Cancer in the United States Double That of Canada, with No Survival Benefitc
By Phoebe Starr
Economics & Value, Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Healthcare costs in the United States have spiraled out of control, and polls show that single-payer healthcare is gaining traction.
Read Article
Next-Generation Sequencing More Cost-Effective and Faster Than Single-Gene Testing
By Phoebe Starr
Economics & Value, Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“NGS decreased the cost of testing, identified the highest percentage of targetable genetic alterations, and had the fastest turnaround,” reported Nathan A. Pennell, MD, PhD.
Read Article

Page 111 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.